Early Fluid Resolution Predicts Faricimab Durability - Summary - MDSpire

Early Fluid Resolution Predicts Faricimab Durability

Post hoc analysis suggests rapid retinal fluid resolution may help identify patients with nAMD who can maintain longer faricimab dosing intervals.

  • By

  • Conexiant News Staff

  • March 11, 2026

  • 4 min

Share

Objective:

To determine if early resolution of retinal fluid after initiating faricimab therapy can predict longer treatment intervals in patients with neovascular age-related macular degeneration (nAMD).

Approach:
    Key Findings:
    • 265 out of 552 participants achieved resolution of intraretinal fluid (IRF) and subretinal fluid (SRF) within the first 12 weeks.
    • Patients with early fluid resolution were nearly twice as likely to receive every-16-week dosing compared to every-8-week dosing.
    • At week 112, those with early fluid resolution were more likely to remain on extended dosing intervals.
    Interpretation:

    Early anatomical response, indicated by fluid resolution, may serve as a predictor of treatment durability with faricimab, potentially allowing for longer intervals between treatments.

    Limitations:
    • Findings are based on a post hoc analysis, which may limit the strength of the conclusions.
    • Further validation in prospective studies is needed to confirm the predictive value of early fluid resolution.
    Conclusion:

    Identifying early predictors of treatment durability could help tailor treatment strategies and reduce the injection burden for patients with nAMD.

    Sources:

Original Source(s)

Early Fluid Resolution Predicts Faricimab Durability

  • by Conexiant News Staff

  • March 11, 2026

Related Content

Optimizing IOL Calculations With AI

AI has the potential to optimize and validate medical decision-making, with a particularly high expertise currently focused on ophthalmology.

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

Supplying Ocular Nutritional Supplements

Supplying ocular nutritional supplements (ONS) is a way to deepen patient trust and improve their visual outcomes, with the byproduct a new revenue stream. This is the theme of this issue of Optometric Management.